These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 17577775

  • 1. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R.
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [Abstract] [Full Text] [Related]

  • 2. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, Takahashi H, Onda K, Takahashi H, Tanaka R.
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [Abstract] [Full Text] [Related]

  • 3. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R, Morii K, Shinbo Y, Homma J, Sano M, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Kakuma T, Tanaka R.
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI.
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
    Somers R, Carde P, Thomas J, Tirelli U, Keuning JJ, Bron D, Delmer A, de Bock R, De Wolf-Peeters C, Keunig JJ.
    Ann Oncol; 1994 Jan; 5 Suppl 2():85-9. PubMed ID: 7515651
    [Abstract] [Full Text] [Related]

  • 14. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK.
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [Abstract] [Full Text] [Related]

  • 15. Advances in chemotherapy for large cell lymphoma.
    Coleman M, Gerstein G, Topilow A, Lebowicz J, Berhardt B, Chiarieri D, Silver RT, Pasmantier MW.
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, Ponzoni M, Terreni MR, Tomirotti M, Spina M, Villa E.
    Oncology; 2001 Apr; 60(2):134-40. PubMed ID: 11244328
    [Abstract] [Full Text] [Related]

  • 20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.